What are analysts'target prices for Ayala Pharmaceuticals'stock?
6 brokers have issued 12-month target prices for Ayala Pharmaceuticals' stock. Their forecasts range from $17.00 to $29.00. On average, they expect Ayala Pharmaceuticals' share price to reach $23.33 in the next twelve months.
What is the Alyi stock price prediction for 2026-12-04?
Based on our forecasts, a long-term increase is expected, the "ALYI" stock price prognosis for 2026-12-04 is 0.0438 USD. With a 5-year investment, the revenue is expected to be around +231.94%.
Where can I buy Ayla shares?
Shares of AYLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
Is Alyi a sell or buy on Robinhood?
Today ALYI ranks #8329 as sell candidate. Get a Free Stock at Robinhood Which way will ALYI go? This stock may move very much during the day (volatility) and with periodic low trading volume this stock is considered to be "very high risk".
Is Alyi a good stock to buy now?
Based on our forecasts, a long-term increase is expected, the "ALYI" stock price prognosis for 2027-06-04 is 0.0123 USD. With a 5-year investment, the revenue is expected to be around +295.94%. Your current $100 investment may be up to $395.94 in 2027. Get It Now!
Where can I buy Alternet stock?
You can purchase shares of Alternet Systems (OTCPK: ALYI) through any online brokerage.
Is Alternet Systems Inc a real company?
Alternet Systems, Inc. builds an electric mobility ecosystem. The Company The Company develops and manufactures electric motorcycle. Alternet Systems serves customers in the United States.
How many shares does Alyi have?
Share StatisticsAvg Vol (3 month) 313.03MShares Outstanding 5116.72MImplied Shares Outstanding 6N/AFloat 8107.06M% Held by Insiders 113.77%7 more rows
What kind of company is Alyi?
Alternet Systems Inc (OTC Pink - Current Information:ALYI) It offers lithium battery-powered motorcycles and motorbikes. The company was founded on June 26, 2000 and is headquartered in Addison, TX.
About Alternet Systems, Inc
Golden Star Signal
Alternet Systems, Inc., through its subsidiaries, focuses on providing digital payments and data analytics, micro segmentation, and marketing intelligence services for the mass consumer goods, payments, financial services, and telecommunications sectors.
Alternet Systems Inc ( ALYI ) Stock Market info
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Also on walletinvestor.com
Recommendations: Buy or sell Alternet Systems stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Alternet Systems share forecasts, stock quote and buy / sell signals below.
What is the AYLA symbol?
Term Box: Best Alternet Systems Inc forecast, ALYI stock price prediction, ALYI forecast, Alternet Systems Inc finance tips, ALYI prediction, Alternet Systems Inc analyst report, ALYI stock price predictions 2022, Alternet Systems Inc stock forecast, ALYI forecast tomorrow, Alternet Systems Inc technical analysis, ALYI stock future price, Alternet Systems Inc projections, Alternet Systems Inc market prognosis, ALYI expected stock price..
What is Ayala Pharmaceuticals?
Ayala Pharmaceuticals trades on the NASDAQ under the ticker symbol "AYLA."
Does Ayala Pharmaceuticals pay dividends?
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, an oral injectable small molecule GSI that is in Phase I clinical trial for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
What is Ayala Pharmaceuticals?
Ayala Pharmaceuticals does not currently pay a dividend.
When is Ayala meeting 2021?
(NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Roni Mamluk, Ph.D., Chief Executive Officer of Ayala, will participate in two upcoming virtual investor conferences: Jefferies Virtual Healthcare Conference: Fireside Chat – Wednesday, June 2, 2021 at 3:00 pm ET.Raymond James Human Health Innovation Conference: Corporate Presentation – Monday, June 21, 2021 at 10:00 am ET. A live webcast of each event may be accessed by visiting the Events & Presentations section of Ayala’s website at ir.ayalapharma.com. An archived replay of each webcast will be available on the website for approximately 90 days following the presentations. About Ayala PharmaceuticalsAyala Pharmaceuticals, Inc. is a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. Ayala’s approach is focused on predicating, identifying and addressing tumorigenic drivers of cancer through a combination of its bioinformatics platform and next-generation sequencing to deliver targeted therapies to underserved patient populations. The company has two product candidates under development, AL101 and AL102, targeting the aberrant activation of the Notch pathway with gamma secretase inhibitors to treat a variety of tumors including Adenoid Cystic Carcinoma, Triple Negative Breast Cancer (TNBC), T-cell Acute Lymphoblastic Leukemia (T-ALL), Desmoid Tumors and Multiple Myeloma (MM) (in collaboration with Novartis). AL101, has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA and is currently in a Phase 2 clinical trial for patients with ACC (ACCURACY) bearing Notch activating mutations and in a Phase 2 clinical trial for patients with TNBC (TENACITY) bearing Notch activating mutations and other gene rearrangements. AL102 is currently being advanced to a Phase 2/3 clinical trials for patients with desmoid tumors (RINGSIDE) and is being evaluated in a Phase 1 clinical trial in combination with Novartis’ BMCA targeting agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma. For more information, visit www.ayalapharma.com. Contacts: Investors:Julie SeidelStern Investor Relations, Inc. [email protected] Ayala Pharmaceuticals:[email protected]
What is the Vickers top buyer and seller report?
REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announced that Ayala management will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 17, 2021 at 5:00pm GMT (12:00pm ET). A live webcast of the fireside chat may be
Is Ayala a clinical stage company?
Daily – Vickers Top Buyers & Sellers for 08/23/2021 The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
